Journal of Diabetes Research / 2015 / Article / Tab 1

Clinical Study

Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

Table 1

Baseline demographics of the study subjects.

Bromocriptine-QR treatment group ()Reference group ()

Age (years)46 ± 354 ± 3
Gender (% female)8840
Race63% B; 25% H; 12% W60% B; 40% H; 0% W
Weight (lbs)252.3 ± 20227.2 ± 17.4
BMI46.2 ± 5.937.1 ± 5.3*
Duration of diabetes (years)13.7 ± 2.212.6 ± 3.5
HbA1c9.74 ± 0.569.68 ± 0.74
Total daily dose of insulin (units) 199 ± 33105 ± 41

*Mean does not include one double amputee subject.
B: black; H: Hispanic; W: white; BMI: body mass index.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.